Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 406 Carcinoma, Non-Small-Cell Lung 147 Urinary Bladder Neoplasms 87 Breast Neoplasms 84 Cholangiocarcinoma 82 Lung Neoplasms 78 Neoplasm Metastasis 67 Neoplasms 64 Biliary Tract Neoplasms 58 Nasopharyngeal Carcinoma 53 Ovarian Neoplasms 46 Sarcoma 43 Recurrence 39 Gallbladder Neoplasms 39 Hodgkin Disease 34 Lymphoma, Large B-Cell, Diffuse 33 Lymphoma 32 Carcinoma, Transitional Cell 29 Bile Duct Neoplasms 24 Adenocarcinoma 23 Fallopian Tube Neoplasms 19 Carcinoma, Hepatocellular 19 Adenocarcinoma of Lung 18 Triple Negative Breast Neoplasms 17 Lymphoma, Non-Hodgkin 17 Liver Neoplasms 17 Nasopharyngeal Neoplasms 16 Lymphoma, Extranodal NK-T-Cell 16 Carcinoma 16 Non-Muscle Invasive Bladder Neoplasms 15

Interventions

Fulvestrant 6 olaparib 4 Letrozole 4 trastuzumab deruxtecan 3 Aromatase Inhibitors 3 Anastrozole 3 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Paclitaxel 2 Goserelin 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Capecitabine 2 toripalimab 1 talazoparib 1 sonidegib 1 ribociclib 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 elacestrant 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × Gemcitabine × Clear all

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡